Effect of Cinnamon and Chromium Picolinate supplementation on Hemoglobin A1c in Patients with Type 1 Diabetes.

Evaluation and comparison of the effect of Cinnamon and Chromium Picolinate supplementation on Hemoglobin A1c in Patients with Type 1 Diabetes mellitus.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230501058037N1

Enrollment

Registered

2023-06-19

Start date

2022-05-21

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes. Type 1 diabetes mellitus without complications

Interventions

Intervention 1: The first intervention group: 180 capsules containing 500 mg cinnamon of Synabetic brand for using 2 times per day were provided to each patient in two 90 days courses, and the patien

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Type 1 diabetes has been diagnosed for 18 months before entering the study Patients must be less than 18 years old when entering the study Refer to Mofid hospital clinic for routine care Patients have not taken medicinal plants or other supplements in the last 8 weeks Do not be allergic to supplements

Exclusion criteria

Exclusion criteria: Patients do not have a history of hospitalization for medical or psychiatric reasons in the last 12 months It is not possible to access by phone Pregnancy or breastfeeding Hemoglobinopathy Acute infection (pneumonia, urinary tract infection, otitis)

Design outcomes

Primary

Measure	Time frame
Age Of The Patient. Timepoint: At The Beginning Of The Study. Method of measurement: Questionnaire-Clinical File.;Gender Of The Patient. Timepoint: At The Beginning Of The Study. Method of measurement: Questionnaire-Clinical File.;Height Of The Patient. Timepoint: At The Beginning Of The Study. Method of measurement: Meter.;Patient Weight. Timepoint: At The Beginning Of The Study. Method of measurement: Scales.;Body Mass Index. Timepoint: At The Beginning Of The Study. Method of measurement: Questionnaire-Clinical File.;Duration of diagnosis. Timepoint: At The Beginning Of The Study. Method of measurement: Questionnaire-Clinical File.;The Stage Of Maturation Of The Patient. Timepoint: At The Beginning Of The Study. Method of measurement: Questionnaire-Clinical File.;Fasting Blood Sugar. Timepoint: At the beginning of the study, day 90 and day 180 in patients. Method of measurement: Paraclinic – Laboratory.;Hemoglobin A1C. Timepoint: At the beginning of the study, day 90 and day 180 in patients. Method of measurement: Paraclinic – Laboratory.;Triglyceride. Timepoint: At the beginning of the study, day 90 and day 180 in patients. Method of measurement: Paraclinic – Laboratory.;TYG index. Timepoint: At the beginning of the study, day 90 and day 180 in patients. Method of measurement: Paraclinic – Laboratory.;Insulin Carbohydrate Ratio. Timepoint: At the beginning of the study, day 90 and day 180 in patients. Method of measurement: Paraclinic – Laboratory.;Daily Use of Insulin. Timepoint: At the beginning of the study, day 90 and day 180 in patients. Method of measurement: Questionnaire-Clinical File.	—

Measure

Time frame

Age Of The Patient. Timepoint: At The Beginning Of The Study. Method of measurement: Questionnaire-Clinical File.;Gender Of The Patient. Timepoint: At The Beginning Of The Study. Method of measurement: Questionnaire-Clinical File.;Height Of The Patient. Timepoint: At The Beginning Of The Study. Method of measurement: Meter.;Patient Weight. Timepoint: At The Beginning Of The Study. Method of measurement: Scales.;Body Mass Index. Timepoint: At The Beginning Of The Study. Method of measurement: Questionnaire-Clinical File.;Duration of diagnosis. Timepoint: At The Beginning Of The Study. Method of measurement: Questionnaire-Clinical File.;The Stage Of Maturation Of The Patient. Timepoint: At The Beginning Of The Study. Method of measurement: Questionnaire-Clinical File.;Fasting Blood Sugar. Timepoint: At the beginning of the study, day 90 and day 180 in patients. Method of measurement: Paraclinic – Laboratory.;Hemoglobin A1C. Timepoint: At the beginning of the study, day 90 and day 180 in patients. Method of measurement: Paraclinic – Laboratory.;Triglyceride. Timepoint: At the beginning of the study, day 90 and day 180 in patients. Method of measurement: Paraclinic – Laboratory.;TYG index. Timepoint: At the beginning of the study, day 90 and day 180 in patients. Method of measurement: Paraclinic – Laboratory.;Insulin Carbohydrate Ratio. Timepoint: At the beginning of the study, day 90 and day 180 in patients. Method of measurement: Paraclinic – Laboratory.;Daily Use of Insulin. Timepoint: At the beginning of the study, day 90 and day 180 in patients. Method of measurement: Questionnaire-Clinical File.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShirin Ghane Fard

Shahid Beheshti University of Medical Sciences

Sh.ghanefard@sbmu.ac.ir+98 21 2222 7021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026